Causes and Symptoms of Congestive Heart Failure and Cardiac Arrest Remedy
Watch the Above Video to have More Information on Heart Failure Symptoms and Reasons
Chandigarh: JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest-growing pharmaceutical companies in India, announced a substantial price decrease of approximately 50% for the critical heart failure drug "Azmarda". Azmarda, which contains the patented molecule Saccubutril-Valsartan is indicated for Heart failure which ails 8 to 12 million people in the country. After the price reduction, Azmarda (Saccubutril-Valsartan®), 50 mg will be available at INR 39.6 per tablet as compared to INR 78 per tablet. 35.7% of the Punjab population is hypertensive, which is one of the important risk factors for heart failure. The price reduction will make the management of heart failure more affordable and accessible for people from all strata of society.
Commenting on the move, Dilip Singh Rathore, President - Domestic Business, JB Pharma, said, "Being a leading player in the cardiac segment, JB has decided to take the lead in making their Azmarda drug more accessible and affordable for heart failure patients in India. This is in line with our strategy of providing innovative and quality treatment to a larger patient pool at the most affordable price points. With this move, the overall monthly treatment cost will reduce significantly from INR 4500 to INR 2200. The HF drug also helps in reducing hospitalization cost by around INR 1,00,000 at the minimum. The drug with reduced MRP is available to consumers from December 2022."
While speaking on different aspects of Heart failure during the conference, Dr Rajat Sharma, Consultant Cardiologist, Cardiac Electrophysiologist at Fortis Hospital, Mohali said, "India is more prone to cardiac ailments like Heart failure for being the populous country, and 1 % of the Indian population suffers from Heart failure. Younger Indians die of heart failure 5 times more than that global mortality. It seems that something is amiss in India either we are unable to provide proper treatment or there is a lack of awareness amongst the masses. It is worrisome, and we need to spread more and more awareness about this condition to the people. However, heart failure is not life failure, it is just a condition, which is manageable with proper treatment. When the pumping of the heart, is slowed down for any reason - diabetes or BP, it causes heart failure. The medicines for heart failure play a pivotal role in improving the quality of life."
Throwing light on the heart failure conditions during the conference, Dr U P Singh, Consultant Cardiologist, Prime Diagnostic Centre & Heart Institute, Chandigarh, said, "First, we need to understand what Heart failure is. Heart failure doesn't mean it is the end of life, but it means that the heart is not pumping adequate blood to the body. There are three common symptoms of heart failure - shortness of breath, swelling of legs and fatigue. Once you identify the symptoms, visit the doctor immediately, and get your Heart screening (Echocardiography) done. People with heart failure conditions must adhere to the medicines prescribed by the doctor, and get their BP and weight checked regularly. And most importantly, they should be extra cautious about their diet - take less salt, and don't drink too much water."
"Heart Failure is a devastating condition and it's important to increase awareness about the condition. In that regard, we will also institute 25+ 'Heart failure' clinics in Punjab, and 300+ across the country so that patients can detect this medical condition early and make informed health decisions.," added Mr Rathore.
HF patients were traditionally prescribed only ARBs (Angiotensin receptor blockers) / AI (Ace Inhibitors) as the main medication. Sacubitril+ Valsartan, launched in 2017, is considered superior to ARBs/AIs in raising EF (Ejection Fraction), hence highly effective for HFrEF patients. Sacubitril+ Valsartan is currently prescribed to 30-35% of HFrEF patients while doctors believe the share can go up to 50-65% with the right pricing.
As per IQVIA, MAT Sep 22 data Saccubutril- Valsartan® is now an INR 500+ crores market with a 3-year CAGR of ~30%. The molecule is presently patented by Novartis AG, Switzerland and currently, four companies including Novartis are serving the Indian market. The molecule is expected to go off-patent in January 2023. Presently Azmarda is the third largest brand in the category capturing 17% market share with IQVIA MAT OCT'22 sales of INR 93.5 crores. In April 2022, JB Pharma acquired the Azmarda brand from Novartis AG, Switzerland for the India region for a consideration of INR 246 crores.